Shares of COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) have been given an average rating of “Buy” by the six analysts that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $47.40.
CMPS has been the topic of a number of recent research reports. Royal Bank of Canada assumed coverage on COMPASS Pathways in a research report on Tuesday, July 23rd. They issued an “outperform” rating and a $23.00 target price on the stock. Canaccord Genuity Group lowered their price objective on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, August 2nd. HC Wainwright restated a “buy” rating and set a $120.00 target price on shares of COMPASS Pathways in a report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, June 21st.
Read Our Latest Analysis on COMPASS Pathways
Institutional Inflows and Outflows
COMPASS Pathways Stock Up 3.5 %
COMPASS Pathways stock opened at $7.19 on Friday. The company has a 50 day moving average of $6.84 and a 200-day moving average of $8.28. The company has a quick ratio of 15.23, a current ratio of 15.23 and a debt-to-equity ratio of 0.12. COMPASS Pathways has a twelve month low of $5.01 and a twelve month high of $12.75. The stock has a market capitalization of $491.66 million, a PE ratio of -3.03 and a beta of 2.27.
COMPASS Pathways (NASDAQ:CMPS – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). During the same period in the previous year, the business earned ($0.62) EPS. On average, equities research analysts anticipate that COMPASS Pathways will post -2.24 EPS for the current fiscal year.
About COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Recommended Stories
- Five stocks we like better than COMPASS Pathways
- Quiet Period Expirations Explained
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- 3 Small Caps With Big Return Potential
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- How to Use Stock Screeners to Find Stocks
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.